Clinical Research Directory
Browse clinical research sites, groups, and studies.
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.
Official title: Placebo-Controlled Phase II Randomized Clinical Trial of Photobiomodulation Therapy in Head and Neck Cancer Survivors With Chronic Lymphedema
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-01-15
Completion Date
2029-11-30
Last Updated
2026-01-21
Healthy Volunteers
No
Interventions
LTU-904 Portable Laser Therapy Unit (active laser device)
The RianCorp LTU-904 laser therapy unit (active laser device) will be used for photobiomodulation therapy (PBMT).
LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)
The RianCorp LTU-904 laser therapy (sham/inactive laser device) unit will be used for sham therapy.
Locations (2)
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States